We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OncoHost Logo

OncoHost

OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. Their mission is to translate the predictive power of proteomics into improved, truly personalized care that makes a real difference in the lives of patients worldwide.

Latest OncoHost Content

Cancer seen in the lungs of a human torso
Industry Insight

Addressing One of the Most Common Dilemmas Faced by Oncologists

Technology Networks spoke to Dr. Ofer Sharon, CEO of OncoHost, to learn about the challenges in non-small cell lung cancer treatment and how proteomics-based analysis could enable personalized cancer treatments.
A doctor holding a clipboard with a patient.
Product News

OncoHost To Present Proteomics-Based Predictive Biomarker for Immune-Related Adverse Events in NSCLC Patients

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.
Oncohost logo.
Product News

OncoHost To Present PROphet® Biomarker Model That Accurately Predicts Clinical Benefit to ICI-Based Treatment

OncoHost has announced that it will give a poster presentation demonstrating the accuracy of its PROphet® biomarker model at the upcoming American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023, in Chicago, Illinois.
Connecting hexagons each with a symbol relating to health, medicine and data.
Industry Insight

The Impact of Proteomics on Precision Oncology

To find out more about how proteomics is providing new insights into cancer dynamics and resistance mechanisms, we spoke to Dr. Ofer Sharon, CEO of OncoHost, a precision diagnostics company.
The OncoHost logo
Product News

OncoHost To Present Proteomics-Based Biomarker Model for Clinical Benefit to Immunotherapy in NSCLC Patients at SITC 2022

OncoHost has developed a novel predictive model for clinical benefit of immune checkpoint inhibitor in non-small cell lung cancer patients.
SomaLogic Announces License Agreement With OncoHost for the Development of Precision Cancer Diagnostics content piece image
Product News

SomaLogic Announces License Agreement With OncoHost for the Development of Precision Cancer Diagnostics

SomaLogic has announced it has signed a licensing agreement with OncoHost.
Driving Progress in Personalized Cancer Therapy content piece image
Industry Insight

Driving Progress in Personalized Cancer Therapy

Personalized medicine has the potential to change the cancer patient's journey by predicting how they will respond to different treatments. Technology Networks spoke to Dr. Ofer Sharon, CEO of OncoHost, to find out more!
Advertisement